These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

118 related items for PubMed ID: 29947280

  • 1. In silico screening and identification of potential GSK3β inhibitors.
    Daggupati T, Pamanji R, Yeguvapalli S.
    J Recept Signal Transduct Res; 2018 Aug; 38(4):279-289. PubMed ID: 29947280
    [Abstract] [Full Text] [Related]

  • 2. Identification of two potential glycogen synthase kinase 3β inhibitors for the treatment of osteosarcoma.
    Lu K, Wang X, Chen Y, Liang D, Luo H, Long L, Hu Z, Bao J.
    Acta Biochim Biophys Sin (Shanghai); 2018 May 01; 50(5):456-464. PubMed ID: 29546355
    [Abstract] [Full Text] [Related]

  • 3. Discovery of novel and highly potential inhibitors of glycogen synthase kinase 3-beta (GSK-3β) through structure-based pharmacophore modeling, virtual computational screening, docking and in silico ADMET analysis.
    Benghanem S, Mesli F, Fatima Zohra HA, Nacereddine C, Hadjer C, Abdellatif M.
    J Biomol Struct Dyn; 2024 Sep 01; 42(14):7091-7106. PubMed ID: 37498130
    [Abstract] [Full Text] [Related]

  • 4. Theoretical Studies on the Selectivity Mechanisms of Glycogen Synthase Kinase 3β (GSK3β) with Pyrazine ATP-competitive Inhibitors by 3DQSAR, Molecular Docking, Molecular Dynamics Simulation and Free Energy Calculations.
    Zhu J, Wu Y, Xu L, Jin J.
    Curr Comput Aided Drug Des; 2020 Sep 01; 16(1):17-30. PubMed ID: 31284868
    [Abstract] [Full Text] [Related]

  • 5. Identification of dual kinase inhibitors of CK2 and GSK3β: combined qualitative and quantitative pharmacophore modeling approach.
    Pardhi T, Vasu K.
    J Biomol Struct Dyn; 2018 Jan 01; 36(1):177-194. PubMed ID: 27960601
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Identification of novel scaffold of benzothiazepinones as non-ATP competitive glycogen synthase kinase-3β inhibitors through virtual screening.
    Zhang P, Hu HR, Huang ZH, Lei JY, Chu Y, Ye DY.
    Bioorg Med Chem Lett; 2012 Dec 01; 22(23):7232-6. PubMed ID: 23099099
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. An emerging strategy for cancer treatment targeting aberrant glycogen synthase kinase 3 beta.
    Miyashita K, Nakada M, Shakoori A, Ishigaki Y, Shimasaki T, Motoo Y, Kawakami K, Minamoto T.
    Anticancer Agents Med Chem; 2009 Dec 01; 9(10):1114-22. PubMed ID: 19925395
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Investigation of the bindings of a class of inhibitors with GSK3β kinase using thermodynamic integration MD simulation and kinase assay.
    Hsu CJ, Hsu WC, Lee DJ, Liu AL, Chang CM, Shih HJ, Huang WH, Lee-Chen GJ, Hsieh-Li HM, Lee GC, Sun YC.
    Chem Biol Drug Des; 2017 Aug 01; 90(2):272-281. PubMed ID: 28127860
    [Abstract] [Full Text] [Related]

  • 13. E-pharmacophore-based virtual screening to identify GSK-3β inhibitors.
    Natarajan P, Priyadarshini V, Pradhan D, Manne M, Swargam S, Kanipakam H, Bhuma V, Amineni U.
    J Recept Signal Transduct Res; 2016 Oct 01; 36(5):445-58. PubMed ID: 27305963
    [Abstract] [Full Text] [Related]

  • 14. Biological basis and clinical study of glycogen synthase kinase- 3β-targeted therapy by drug repositioning for glioblastoma.
    Furuta T, Sabit H, Dong Y, Miyashita K, Kinoshita M, Uchiyama N, Hayashi Y, Hayashi Y, Minamoto T, Nakada M.
    Oncotarget; 2017 Apr 04; 8(14):22811-22824. PubMed ID: 28423558
    [Abstract] [Full Text] [Related]

  • 15. Discovery of new GSK-3β inhibitors through structure-based virtual screening.
    Dou X, Jiang L, Wang Y, Jin H, Liu Z, Zhang L.
    Bioorg Med Chem Lett; 2018 Jan 15; 28(2):160-166. PubMed ID: 29208522
    [Abstract] [Full Text] [Related]

  • 16. Integrating Machine Learning-Based Virtual Screening With Multiple Protein Structures and Bio-Assay Evaluation for Discovery of Novel GSK3β Inhibitors.
    Zhu J, Wu Y, Wang M, Li K, Xu L, Chen Y, Cai Y, Jin J.
    Front Pharmacol; 2020 Jan 15; 11():566058. PubMed ID: 33041806
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Xanthone glucoside 2-β-D-glucopyranosyl-1,3,6,7-tetrahydroxy-9H-xanthen-9-one binds to the ATP-binding pocket of glycogen synthase kinase 3β and inhibits its activity: implications in prostate cancer and associated cardiovascular disease risk.
    Mangangcha IR, Brojen Singh RK, Lebeche D, Ali S.
    J Biomol Struct Dyn; 2022 Oct 15; 40(17):7868-7884. PubMed ID: 33769184
    [Abstract] [Full Text] [Related]

  • 19. Binding and stability of indirubin-3-monoxime in the GSK3β enzyme: a molecular dynamics simulation and binding free energy study.
    Saravanan K, Hunday G, Kumaradhas P.
    J Biomol Struct Dyn; 2020 Mar 15; 38(4):957-974. PubMed ID: 30963817
    [Abstract] [Full Text] [Related]

  • 20. Identification and in vitro evaluation of new leads as selective and competitive glycogen synthase kinase-3β inhibitors through ligand and structure based drug design.
    Darshit BS, Balaji B, Rani P, Ramanathan M.
    J Mol Graph Model; 2014 Sep 15; 53():31-47. PubMed ID: 25064440
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.